Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Damora Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +3 vs. Q2 2022
- Shares held
- 9.16M
- +60.2K (+0.7%) vs. Q2 2022
- Total value
- $17.3M
- +$1.57M (+10.0%) vs. Q2 2022
- New holders
- 4
- 7 more added
- Sold out
- 1
- 4 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 854 | $2.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 2,994 | $5.00K | 0.00% | +8+0.3% | Added |
| Tower Research Capital LLC (TRC) | 3,015 | $6.00K | 0.00% | +423+16.3% | Added |
| UBS Group AG | 4,097 | $8.00K | 0.00% | +4,097 | New |
| Simplex Trading, LLC | 9,608 | $18.0K | 0.00% | +9,123+1,881.0% | Added |
| Commonwealth Equity Services, LLC | 10,179 | $19.0K | 0.00% | +10,179 | New |
| BlackRock Inc. | 16,661 | $31.0K | 0.00% | +2,497+17.6% | Added |
| Millennium Management LLC | 18,795 | $36.0K | 0.00% | −11,562−38.1% | Reduced |
| Northern Trust Corp | 20,551 | $39.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 34,219 | $65.0K | 0.00% | 00.0% | Unchanged |
| FNY Investment Advisers, LLC | 42,000 | $79.0K | 0.05% | +42,000 | New |
| State Street Corp | 44,906 | $85.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 46,544 | $88.0K | 0.00% | −16,751−26.5% | Reduced |
| Bank of America Corp | 46,838 | $89.0K | 0.00% | +9,826+26.5% | Added |
| Susquehanna International Group, LLP | 52,722 | $99.0K | 0.00% | +52,722 | New |
| Federated Hermes, Inc. | 60,000 | $113.0K | 0.00% | +20,000+50.0% | Added |
| Marquette Asset Management, LLC | 60,244 | $114.0K | 0.04% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 92,000 | $174.0K | 0.00% | −12,900−12.3% | Reduced |
| Geode Capital Management, LLC | 106,136 | $200.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 173,100 | $327.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 179,300 | $339.0K | 0.00% | −67,411−27.3% | Reduced |
| Laurion Capital Management LP | 190,652 | $360.0K | 0.01% | 00.0% | Unchanged |
| MAI Capital Management | 338,915 | $641.0K | 0.01% | +18,055+5.6% | Added |
| Cormorant Asset Management, LP | 1,020,238 | $1.93M | 0.14% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,497,791 | $4.72M | 0.23% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 4,090,937 | $7.73M | 0.15% | 00.0% | Unchanged |
| Curi Capital | 0 | $0 | 0.00% | −76−100.0% | Sold out |